Phase 2 trial showing the potential efficacy of the oral, small molecule, GLP-1 receptor agonist, orforglipron in people with type 2 diabetes 31.Pfizer announces topline phase 2b results of oral GLP-1R agonist, danuglipron, in adults with obesity
10 M rapamycin alone did not affect the neomycin dose-response curve (Figure 6B)
FOXO4-DRI is a novel peptide derived from the forkhead box O (FOXO) transcription factor, which plays a critical role in regulating cellular stress responses, apoptosis, and longevity
Athletes should not assume peptides are undetectable , even if they do not appear on routine workplace screens
The inflammatory response in the MPTP model of Parkinsons disease is mediated by brain angiotensin: relevance to progression of the disease